查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
北美药物动力学服务市场预测至 2031 年 - 区域分析 - 按药物类型、服务类型、治疗应用和最终用户
市场调查报告书
商品编码
1597063

北美药物动力学服务市场预测至 2031 年 - 区域分析 - 按药物类型、服务类型、治疗应用和最终用户

North America Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type, Service Type, Therapeutic Application, and End User
出版日期: | 出版商: The Insight Partners | 英文 87 Pages | 订单完成后即时交付

价格

2023年北美药物动力学服务市值为3.7536亿美元，预计2031年将达到6.9277亿美元；预计2023年至2031年复合年增长率为8.0%。

药物动力学研究应用范围的扩大推动北美药物动力学服务市场

药物动力学研究用于确定多个参数，例如人体等效剂量 (HED) 水平、未观察到效应水平 (NOEL) 和药物动力学/药效学测试。进行的任何临床前计划的主要重点是支持对药物动力学研究测试的安全有效剂量范围的分析。多项毒理学研究对 NOEL（即不会产生不良反应的最高剂量）进行了资料分析。如果缺乏临床药物动力学资料，则该剂量水平会在比较体表面积的基础上进一步转换为 HED 水平。了解潜在候选药物的药物动力学特征在药物发现计划中起着重要作用。监管机构在推动药物动力学研究的实施方面发挥着重要作用。这些研究也有助于优化为住院患者提供的药物护理服务。 PK模型常用于确定药物暴露量、药物浓度以分析最佳剂量，并分析药物在人体内的分布。医疗保健提供者实施 PK 原则来设计监测药物浓度、某些药物的剂量，最大限度地提高预期治疗效果并最大限度地减少毒性。

北美药物动力学服务市场概况

美国占据北美药物动力学服务市场的最大份额。该国已成为领先的临床研究目的地；它约占全球临床试验总数的 50%。成熟的医疗基础设施、快速的审批时间表和有利的监管框架为药物研究公司进行临床试验创造了有利的环境。此外，在美国进行的试验中产生的资料在全球范围内被接受。根据世界卫生组织 (WHO) 的报告，美国 2021 年登记的临床试验数量最多（157,618 项）。

北美药物动力学服务市场收入及 2031 年预测（百万美元）

北美药物动力学服务市场细分

北美药物动力学服务市场分为药物类型、服务类型、治疗应用、最终用户和国家。

根据药物类型，北美药物动力学服务市场分为小分子、大分子和疫苗。 2023 年，小分子细分市场占据最大的市场份额。

从服务类型来看，北美药物动力学服务市场分为临床前ADME和人体研究、PK/PD分析和报告、给药模拟、风险分析等。 2023 年，临床前 ADME 和人体研究领域占据最大的市场份额。

依治疗应用，北美药物动力学服务市场分为肿瘤学、传染病、神经系统疾病、自体免疫疾病、妇科疾病、心血管疾病、呼吸系统疾病等。 2023 年，肿瘤学领域占据最大的市场份额。

依最终用户划分，北美药物动力学服务市场分为製药和生物技术公司、合约研究组织等。 2023 年，合约研究组织细分市场占据最大的市场份额。

依国家/地区划分，北美药物动力学服务市场分为美国、加拿大和墨西哥。 2023 年，美国在北美药物动力学服务市场份额中占据主导地位。

查尔斯河实验室国际公司； Eurofins Scientific SE； Evotec SE；塞塔拉公司； Parexel国际公司；赛默飞世尔科技公司；艾伦特；太平洋生物实验室；和 SGS SA 是北美药物动力学服务市场上的一些领先公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 主要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：北美药物动力学服务市场格局

  • PEST分析

第 5 章：北美药物动力学服务市场 - 主要市场动态

  • 市场驱动因素
    • 慢性病和传染病的盛行率上升
    • 扩大药物动力学研究的应用范围
    • 将药物动力学服务外包给 CRO
  • 市场限制
    • 新兴国家药物动力学服务提供者的覆盖范围有限
  • 市场机会
    • 越来越多地采用体内和体外模型来了解药物动力学的变异性
  • 未来趋势
    • 药物动力学服务中越来越多采用大数据分析
  • 驱动因素和限制的影响：

第 6 章：药物动力学服务市场 - 北美分析

  • 北美药物动力学服务市场收入，2021-2031

第 7 章：北美药物动力学服务市场分析 - 按药物类型

  • 概述
  • 小分子
  • 大分子
  • 疫苗

第 8 章：北美药物动力学服务市场分析 - 按服务类型

  • 概述
  • 临床前 ADME 和人体研究
  • PK/PD 分析和报告
  • 剂量模拟
  • 风险分析
  • 其他的

第 9 章：北美药物动力学服务市场分析 - 按治疗应用

  • 肿瘤学
  • 传染病
  • 神经系统疾病
  • 自体免疫疾病
  • 妇科疾病
  • 心血管疾病
  • 呼吸系统疾病
  • 其他的

第 10 章：北美药物动力学服务市场分析 - 按最终用户

  • 製药和生物技术公司
  • 合约研究组织
  • 其他的

第 11 章：北美药物动力学服务市场 - 国家分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第 12 章：公司简介

  • Charles River Laboratories International Inc
  • Eurofins Scientific SE
  • Evotec SE
  • Certara Inc.
  • Parexel International Corp
  • Thermo Fisher Scientific Inc.
  • Allucent
  • PACIFIC BIOLABS
  • SGS SA

第 13 章：附录

Product Code: BMIRE00030931

The North America pharmacokinetics services market was valued at US$ 375.36 million in 2023 and is expected to reach US$ 692.77 million by 2031; it is estimated to register a CAGR of 8.0% from 2023 to 2031.

Expanding Range of Application of Pharmacokinetic Studies Fuels North America Pharmacokinetics Services Market

Pharmacokinetic studies are being employed to determine several parameters such as human-equivalent doses (HED) level, no-observed effect level (NOEL), and pharmacokinetic/pharmacodynamic testing. The main focus of any pre-clinical program conducted is to support the analysis of a safe and effective dose range for testing in pharmacokinetic studies. Several toxicology studies conducted data on the NOEL, i.e., the highest dose that does not produce adverse effects. This dose level is further converted to a HED level on a comparative body-surface area basis if there is lack of clinical pharmacokinetic data. Understanding the pharmacokinetic profile of a potential drug candidate plays an important role in the drug discovery program. Regulatory authorities play a major role propelling the implementation of pharmacokinetic studies. These studies are also instrumental in optimizing pharmaceutical care services provided to patients admitted in hospitals. The PK model is often applied to determine exposure to drugs, concentrations of drugs to analyze optimal dosage, and analyze the disposition of drugs in the human body. Healthcare providers implement the principles of PK to design monitor drug concentrations, doses of some drugs, maximize the intended therapeutic outcomes and minimize toxicities.

North America Pharmacokinetics Services Market Overview

The US accounts for the largest share of the North America pharmacokinetics services market in North America. The country has emerged as a leading clinical research destination; it accounts for ~50% of the total clinical trials conducted in the world. The availability of established medical infrastructure, fast approval timelines, and favorable regulatory framework create a conducive environment for pharmaceutical research companies to conduct clinical trials. Moreover, the data generated in trials conducted in the US is accepted globally. As per a World Health Organization (WHO) report, the US registered the highest number of clinical trials (157,618) in 2021.

North America Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)

North America Pharmacokinetics Services Market Segmentation

The North America pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.

Based on drug type, the North America pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.

In terms of service type, the North America pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.

By therapeutic application, the North America pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

By end user, the North America pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.

By country, the North America pharmacokinetics services market is segmented into the US, Canada, and Mexico. The US dominated the North America pharmacokinetics services market share in 2023.

Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are some of the leading companies operating in the North America pharmacokinetics services market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Pharmacokinetics Services Market Landscape

  • 4.1 PEST Analysis

5. North America Pharmacokinetics Services Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Chronic and Infectious Diseases
    • 5.1.2 Expanding Range of Application of Pharmacokinetic Studies
    • 5.1.3 Outsourcing of Pharmacokinetics Services to CROs
  • 5.2 Market Restraints
    • 5.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
  • 5.4 Future Trend
    • 5.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
  • 5.5 Impact of Drivers and Restraints:

6. Pharmacokinetics Services Market - North America Analysis

  • 6.1 North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

7. North America Pharmacokinetics Services Market Analysis - by Drug Type

  • 7.1 Overview
  • 7.2 Small Molecule
    • 7.2.1 Overview
    • 7.2.2 Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Large Molecule
    • 7.3.1 Overview
    • 7.3.2 Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Vaccines
    • 7.4.1 Overview
    • 7.4.2 Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Pharmacokinetics Services Market Analysis - by Service Type

  • 8.1 Overview
  • 8.2 Pre-Clinical ADME and Human Studies
    • 8.2.1 Overview
    • 8.2.2 Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 PK/PD Analysis and Reporting
    • 8.3.1 Overview
    • 8.3.2 PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Dosing Simulations
    • 8.4.1 Overview
    • 8.4.2 Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Risk Analysis
    • 8.5.1 Overview
    • 8.5.2 Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Pharmacokinetics Services Market Analysis - by Therapeutic Application

  • 9.1 Oncology
    • 9.1.1 Overview
    • 9.1.2 Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Infectious Diseases
    • 9.2.1 Overview
    • 9.2.2 Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Neurological Disorders
    • 9.3.1 Overview
    • 9.3.2 Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Autoimmune Diseases
    • 9.4.1 Overview
    • 9.4.2 Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.5 Gynecological Disorders
    • 9.5.1 Overview
    • 9.5.2 Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.6 Cardiovascular Diseases
    • 9.6.1 Overview
    • 9.6.2 Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.7 Respiratory Disorders
    • 9.7.1 Overview
    • 9.7.2 Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.8 Others
    • 9.8.1 Overview
    • 9.8.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Pharmacokinetics Services Market Analysis - by End User

  • 10.1 Pharmaceutical and Biotechnology Companies
    • 10.1.1 Overview
    • 10.1.2 Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Contract Research Organization
    • 10.2.1 Overview
    • 10.2.2 Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Others
    • 10.3.1 Overview
    • 10.3.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Pharmacokinetics Services Market - Country Analysis

  • 11.1 North America
    • 11.1.1 North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
      • 11.1.1.1 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.1.1 Overview
        • 11.1.1.1.2 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.1.3 United States: North America Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.1.1.1.4 United States: North America Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.1.1.1.5 United States: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.1.1.1.6 United States: North America Pharmacokinetics Services Market Breakdown, by End User
      • 11.1.1.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.2.1 Overview
        • 11.1.1.2.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.2.3 Canada: North America Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.1.1.2.4 Canada: North America Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.1.1.2.5 Canada: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.1.1.2.6 Canada: North America Pharmacokinetics Services Market Breakdown, by End User
      • 11.1.1.3 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.3.1 Overview
        • 11.1.1.3.2 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.3.3 Mexico: North America Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.1.1.3.4 Mexico: North America Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.1.1.3.5 Mexico: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.1.1.3.6 Mexico: North America Pharmacokinetics Services Market Breakdown, by End User

12. Company Profile

  • 12.1 Charles River Laboratories International Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Eurofins Scientific SE
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Evotec SE
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Certara Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
  • 12.5 Parexel International Corp
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Thermo Fisher Scientific Inc.
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Allucent
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 PACIFIC BIOLABS
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 SGS SA
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms for Pharmacokinetic Services Market

List Of Tables

  • Table 1. North America Pharmacokinetics Services Market Segmentation
  • Table 2. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 3. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 4. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 5. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 6. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 7. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 8. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 9. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 10. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 11. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 12. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 13. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 14. Glossary of Terms

List Of Figures

  • Figure 1. North America Pharmacokinetics Services Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. North America Pharmacokinetics Services Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
  • Figure 6. North America Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
  • Figure 7. Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. North America Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
  • Figure 11. Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. North America Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
  • Figure 17. Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. North America Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
  • Figure 26. Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 29. North America Pharmacokinetics Services Market by Key Countries - Revenue (2023) (US$ Million)
  • Figure 30. North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 31. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 32. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)